Hemophilia Market Report 2026

Hemophilia Market Overview

• Hemophilia market size has reached to $14.98 billion in 2025 • Expected to grow to $23.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth • Market Trend: Major Players In The Hemophilia Market Lead With Innovative Drugs Such As Altuviiio • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hemophilia Market?

Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia. The main types of hemophilia are hemophilia A, hemophilia B, hemophilia C and others. Hemophilia A refers to a genetic disorder characterized by a deficiency of a protein called clotting factor VIII (factor 8). The various treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy and others. These are used by various end-users such as hospitals, clinics, home care settings and others.

What Is The Hemophilia Market Growth Forecast?

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $23.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising adoption of personalized treatment approaches, expansion of home infusion programs, growing investments in rare disease research, increasing focus on quality-of-life improvement. Major trends in the forecast period include increasing adoption of long-acting clotting factor therapies, rising focus on gene therapy for hemophilia, growing use of home-based treatment regimens, expansion of personalized prophylactic treatment plans, enhanced integration of digital patient monitoring.

Global Hemophilia Market Segmentation

1) By Type: Hemophilia A, Hemophilia B, Hemophilia C, Other Types 2) By Treatment: Replacement Therapy, Hemostatic Agents, Desmopressin, Gene Therapy, Other Treatments 3) By End-User: Hospitals, Clinics, Home Care Settings, Other End-Users Subsegments: 1) By Hemophilia A: Severe Hemophilia A, Moderate Hemophilia A, Mild Hemophilia A 2) By Hemophilia B: Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B 3) By Hemophilia C: Severe Hemophilia C, Mild Hemophilia C 4) By Other Types: Acquired Hemophilia, Von Willebrand Disease

What Is The Driver Of The Hemophilia Market?

The rising occurrence of genetic abnormalities is expected to propel the growth of the hemophilia market going forward. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to changes in the DNA sequence of an individual's genes that can result in various health conditions and physical traits. Hemophilia treatment aims to prevent or control bleeding episodes, minimize complications and improve the quality of life for individuals with genetic abnormalities. For instance, in October 2024, according to Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, around 11,148 cystic fibrosis (a genetic disorder) patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year over year. Therefore, the rising occurrence of genetic abnormalities is driving the growth of the hemophilia industry.

Key Players In The Global Hemophilia Market

Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Dimension Therapeutics, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB, Chiesi Farmaceutici S.p.A.

Global Hemophilia Market Trends and Insights

Major companies operating in the hemophilia market are developing innovative drugs such as ALTUVIIIO to sustain their position in the market. For instance, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, launched ALTUVIIIO for hemophilia, which was approved by The Food and Drug Administration (FDA), a US-based government agency. With once-weekly dosing, ALTUVIIIO is the first and only hemophilia A medication to offer regular to near-normal factor activity levels (above 40%) for most of the week and dramatically lessen bleeding compared to previous factor VIII prophylaxis.

What Are Latest Mergers And Acquisitions In The Hemophilia Market?

In February 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company that manufactures drugs for hemophilia, acquired Nimbus Therapeutics LLC for $4 billion. With this acquisition, Takeda strengthens its late-stage pipeline and potentially expands its portfolio and patient impact across multiple indications, reinforcing its ability to maintain strong growth in the mid-to-long term. Nimbus Therapeutics LLC is a US-based pharmaceutical company that manufactures and develops drugs for hemophilia.

Regional Outlook

North America was the largest region in the hemophilia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hemophilia Market?

The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hemophilia Market Report 2026?

The hemophilia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hemophilia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.